Vyvanse (Lisdexamfetamine) is a prodrug comprised of the amino acid L-lysine coupled with dextroamphetamine, hence its chemical name “lis-dexamfetamine.” As a prodrug, Vyvanse is inactive until ingested and enzymatically metabolized into l-lysine (an amino acid) and dextroamphetamine (a psychostimulant), the latter of which has been deemed effective for the treatment of ADHD and binge eating …
Vyvanse (Lisdexamfetamine) is a psychostimulant medication manufactured by Shire Pharmaceuticals for the treatment of ADHD (attention-deficit/hyperactivity disorder). Many consider Vyvanse to be a “new and improved” successor of the drug Adderall. Vyvanse contains the ingredient Lisdexamfetamine which is pharmacologically inactive until metabolized; hence being classified as a “prodrug.” The fact that Vyvanse is a prodrug …
Vyvanse (Lisdexamfetamine) is a drug developed by Shire Pharmaceuticals as a successor to Adderall. Vyvanse was first approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in 2007. In 2015, Vyvanse was approved for binge eating disorder and was found to successfully minimize appetite and number of binge eating episodes per week compared to a placebo. …
Methylphenidate is considered the first medication approved for the treatment of the condition known as “hyperactivity” in the 1960s. As attention-deficit/hyperactivity disorder gained more mainstream attention in the 1990s, the number of diagnoses continued to skyrocket, increasing the demand for new treatments. By the year 1996, mixed amphetamine salts (i.e. Adderall) were approved for the …
With the increasing number of ADHD diagnoses, many individuals are turning to pharmaceutical psychostimulant medications as a means to alleviate symptoms. Historically, one of the most popular and effective treatment options for the treatment of attention-deficit hyperactivity disorder is Adderall, a medication comprised of 75% dextroamphetamine salts and 25% levoamphetamine salts. Adderall’s popularity hasn’t waned …
As of February 2015, the FDA approved the psychostimulant Vyvanse (Lisdexamfetamine) for the treatment of binge eating disorder. In recent years, the popularity of Vyvanse has skyrocketed as an ADHD medication, as well as among those seeking to use it for ulterior purposes such as weight loss, academics, and sports performance. Many consider the medication …
Vyvanse (Lisdexamfetamine) is a psychostimulant medication that was developed by the company Shire. It is primarily prescribed for the treatment of ADHD (attention deficit hyperactivity disorder) and works well to improve cognitive function. In addition to treating ADHD, many doctors have used the drug to help individuals with excessive daytime sleepiness and binge eating disorders. …